RT Journal Article
T1 Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper.
A1 Klimek, Ludger
A1 Jutel, Marek
A1 Bousquet, Jean
A1 Agache, Ioana
A1 Akdis, Cezmi A
A1 Hox, Valerie
A1 Gevaert, Philippe
A1 Tomazic, Peter Valentin
A1 Rondon, Carmen
A1 Cingi, Cemal
A1 Toppila-Salmi, Sanna
A1 Karavelia, Aspasia
A1 Bozkurt, Banu
A1 Forster-Ruhrmann, Ulrike
A1 Becker, Sven
A1 Chaker, Adam M
A1 Wollenberg, Barbara
A1 Mosges, Ralph
A1 Huppertz, Tilman
A1 Hagemann, Jan
A1 Bachert, Claus
A1 Fokkens, Wytske
K1 COVID-19
K1 CRSwNP
K1 SARS-CoV-2
K1 Biologics
K1 Chronic rhinosinusitis
AB Chronic rhinosinusitis is regarded as a chronic airway disease. According to WHO recommendations, it may be a risk factor for COVID-19 patients. In most CRSwNP cases, the inflammatory changes affecting the nasal and paranasal mucous membranes are type-2 (T2) inflammation endotypes. The current knowledge on COVID-19 and on treatment options for CRS was analyzed by a literature search in Medline, Pubmed, international guidelines, the Cochrane Library and the Internet. Based on international literature, on current recommendations by WHO and other international organizations as well as on previous experience, a panel of experts from EAACI and ARIA provided recommendations for the treatment of CRS during the COVID-19 pandemic. Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID-19 infection.
PB John Wiley and Sons
YR 2021
FD 2021-03-06
LK http://hdl.handle.net/10668/16446
UL http://hdl.handle.net/10668/16446
LA en
NO Klimek L, Jutel M, Bousquet J, Agache I, Akdis CA, Hox V, et al. Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper. Allergy. 2021 Mar;76(3):677-688
DS RISalud
RD Apr 20, 2025